This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mortimer, R. H. Articles by Bernus, I. Search for Related Content PubMed PubMed Citation Articles by Mortimer, R. H. Articles by Bernus, I.

Methimazole and Propylthiouracil Equally Cross the Perfused Human Term Placental Lobule¹

Conjoint Endocrine Laboratory (R.H.M., G.R.C., R.S.A., I.B.) and Division of Chemical Pathology (G.R.C., L.P.J., I.B.), Royal Brisbane Hospital, Australia, Q4029; and Departments of Obstetrics and Gynaecology (R.H.M.) and Medicine (M.S.R.), The University of Queensland, Australia Q4072

Address all correspondence and requests for reprints to: Robin Mortimer, Department of Endocrinology, Royal Brisbane Hospital, Herston, Q4029, Australia.

Propylthiouracil (PTU) is widely believed to cross the placenta less freely than methimazole (MMI) and is therefore regarded as the preferred drug for treatment of hyperthyroidism in pregnancy. Clinical studies comparing the two drugs show, however, no differences in maternal or fetal thyroid function. We investigated transfer from the maternal to the fetal circuit in the isolated perfused term human placental lobule of low and high doses of PTU (4 µg/mL and 40 µg/mL) and MMI (1.5 µg/mL and 15 µg/mL) in protein-free perfusate and low doses of both drugs with addition of 40 g/L of bovine albumin. Both drugs readily crossed the placenta, reaching equilibrium in all experiments in about 2 h. Drug concentrations in the two circuits fitted a two compartmental model. Transfer kinetics for the two drugs were similar, nonsaturable, and unaffected by addition of albumin. Clearances (mL·min^-1·g^-1, means ± SD) of PTU from maternal to fetal circuits were: 0.229 ± 0.110, 0.216 ± 0.065, and 0.170 ± 0.032; and for transfer of MMI: 0.165 ± 0.025, 0.232 ± 0.153, and 0.174 ± 0.009 (for low doses without, low doses with, and high doses without albumin, respectively). Clearances of PTU from fetal to maternal circuits were: 0.147 ± 0.072, 0.109 ± 0.014, and 0.116 ± 0.028; and for transfer of MMI: 0.095 ± 0.029, 0.122 ± 0.088, and 0.12 ± 0.005 (in the same experiments). There was no significant difference between drugs or drug doses and no effect of addition of albumin. We conclude that PTU and MMI have similar placental transfer kinetics.

This article has been cited by other articles:

				J. Girling Thyroid disease in pregnancy Obstet Gynaecol (Lond), October 1, 2008; 10(4): 237 - 243. [Abstract] [Full Text] [PDF]

				Subsection Reports J. Clin. Endocrinol. Metab., August 1, 2007; 92(8_suppl): s8 - s47. [Full Text] [PDF]

				M. Abalovich, N. Amino, L. A. Barbour, R. H. Cobin, L. J. De Groot, D. Glinoer, S. J. Mandel, and A. Stagnaro-Green Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., August 1, 2007; 92(8_suppl): s1 - s47. [Abstract] [Full Text] [PDF]

				J. M Chattaway and T. B Klepser Propylthiouracil Versus Methimazole in Treatment of Graves' Disease During Pregnancy Ann. Pharmacother., June 1, 2007; 41(6): 1018 - 1022. [Abstract] [Full Text] [PDF]

				E. N Pearce Diagnosis and management of thyrotoxicosis. BMJ, June 10, 2006; 332(7554): 1369 - 1373. [Full Text] [PDF]

				D. Luton, I. Le Gac, E. Vuillard, M. Castanet, J. Guibourdenche, M. Noel, M.-E. Toubert, J. Leger, C. Boissinot, M.-H. Schlageter, et al. Management of Graves' Disease during Pregnancy: The Key Role of Fetal Thyroid Gland Monitoring J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6093 - 6098. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs N. Engl. J. Med., March 3, 2005; 352(9): 905 - 917. [Full Text] [PDF]

				D. D Streetman and U. Khanderia Diagnosis and Treatment of Graves Disease Ann. Pharmacother., July 1, 2003; 37(7): 1100 - 1109. [Abstract] [Full Text] [PDF]

				A. PINTO and M. GLICK Management of patients with thyroid disease: Oral health considerations J Am Dent Assoc, July 1, 2002; 133(7): 849 - 858. [Abstract] [Full Text] [PDF]

				S. J. Mandel and D. S. Cooper The Use of Antithyroid Drugs in Pregnancy and Lactation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2354 - 2359. [Full Text] [PDF]

				K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Fam Med, August 1, 2000; 9(8): 743 - 747. [Full Text] [PDF]

				M. Knipper, C. Zinn, H. Maier, M. Praetorius, K. Rohbock, I. Kopschall, and U. Zimmermann Thyroid Hormone Deficiency Before the Onset of Hearing Causes Irreversible Damage to Peripheral and Central Auditory Systems J Neurophysiol, May 1, 2000; 83(5): 3101 - 3112. [Abstract] [Full Text] [PDF]

				K. A. Woeber Update on the Management of Hyperthyroidism and Hypothyroidism Arch Intern Med, April 24, 2000; 160(8): 1067 - 1071. [Abstract] [Full Text] [PDF]